Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Other
  • (-) = Other
  • (-) = Tollenaar, R.A.E.M.

Search results

  • RSS Feed
(1 - 9 of 9)
The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era
Hoeijmakers, F.; Schreurs, W.H.; Comans, E.F.I.; Belderbos, J.S.A.; Postmus, P.E.; Tollenaar, R.A.E.M.; Heineman, D.J. 2022
The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era
Other
metadata only
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (vol 5, 4999, 2014)
Ghoussaini, M.; Edwards, S.L.; Michailidou, K.; Nord, S.; Lari, R.C.S.; Desai, K.; ... ; Australian Ovarian Canc Management 2018
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (vol 5, 4999, 2014)
Other
open access
VARIATION IN LYMPH NODE EVALUATION IN RECTAL CANCER, A NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS
Elferink, M.A.G.; Siesling, S.; Lemmens, V.E.P.P.; Visser, O.; Rutten, H.J.; Krieken, J.H.J.M. van; ... ; Tollenaar, R.A.E.M. 2010
VARIATION IN LYMPH NODE EVALUATION IN RECTAL CANCER, A NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS
Other
metadata only
How can you tell if your local breast unit is any good?
Tollenaar, R.A.E.M.; Gooiker, G.A. 2010
How can you tell if your local breast unit is any good?
Other
metadata only
Enhancing the quality of care in patients with breast cancer: seven years experience with a regional audit system
Veerbeek, L.; Geest, L.G.M. van der; Wouters, M.W.J.M.; Dekker, J.W.T.; Nortier, J.W.; Marinelli, A.W.K.S.; ... ; Struikmans, H. 2010
Enhancing the quality of care in patients with breast cancer: seven years experience with a regional audit system
Other
metadata only
The quality indicator 'tumour positive margin rate after breast conserving surgery': a valid assessment of hospital performance?
Gooiker, G.; Veerbeek, L.; Geest, L.G.M. van der; Stijnen, T.; Dekker, J.W.R.; Nortier, J.W.R.; ... ; Tollenaar, R.A.E.M. 2010
The quality indicator 'tumour positive margin rate after breast conserving surgery': a valid assessment of hospital performance?
Other
metadata only
Mass spectrometry based serum protein profiling for the early detection of breast cancer; taking the steps towards clinical implementation
Velstra, B.; Mesker, W.E.; Burgt, Y.E.M. van der; Mertens, B.J.; Deelder, A.M.; Tollenaar, R.A.E.M. 2010
Mass spectrometry based serum protein profiling for the early detection of breast cancer; taking the steps towards clinical implementation
Other
metadata only
The quality indicator 'tumour positive margin rate after breast conserving surgery': a valid assessment of hospital performance?
Gooiker, G.; Veerbeek, L.; Geest, L.G.M. van der; Stijnen, T.; Dekker, J.W.R.; Nortier, J.W.R.; ... ; Tollenaar, R.A.E.M. 2010
The quality indicator 'tumour positive margin rate after breast conserving surgery': a valid assessment of hospital performance?
Other
metadata only
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy
Iersel, L.B.J. van; Koopman, M.; Velde, C.J.H.V. de; Mol, L.; Meerten, E.L.V.P. van; Hartgrink, H.H.; ... ; Gelderblom, H. 2010
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy
Other
metadata only
BACKGROUND: To compare the median overall survival of patients with isolated nonresectable liver metastases in comparable groups of patients treated with either isolated hepatic perfusion (IHP)... Show moreBACKGROUND: To compare the median overall survival of patients with isolated nonresectable liver metastases in comparable groups of patients treated with either isolated hepatic perfusion (IHP) with melphalan or systemic chemotherapy. PATIENTS AND METHODS: Colorectal cancer patients with isolated liver metastases, who underwent IHP, were included in this study. The control group consisted of a subgroup of colorectal cancer patients with liver metastases only, who were enrolled in the randomized CApecitabine, IRinotecan, Oxaliplatin (CAIRO) phase III study. RESULTS: Ninety-nine patients were treated with IHP, and 111 patients were included in the control group. All patient characteristics were comparable except for age. Median follow-up was 78.1 months for IHP versus 54.7 months in the control group. Median overall survival was 25.0 [95% confidence interval (CI) 19.4-30.6] months for IHP and 21.7 (95% CI 19.6-23.8) months for systemic treatment and did not differ significantly (P = 0.29). Treatment-related mortality was 2% for the systemic treatment and 6% for IHP (P = 0.11). CONCLUSION: Compared with a patient group with comparable characteristics treated with systemic chemotherapy, IHP does not provide a benefit in overall survival in patients with isolated nonresectable colorectal liver metastases. Currently, the use of IHP cannot be advocated outside the scope of clinical studies. Show less